The authors present a comparative assessment of the efficiency of balanced and unbalanced crystalloid solutions used in the program of infusion therapy in patients with blood loss. It was found that infusion therapy with unbalanced crystalloid solution facilitated the appearance of electrolytic changes and decrease of pH of venous blood while infusion therapy with balanced crystalloid solution did not cause negative changes of the water-electrolytic and acid-base balance.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
HSP-CAR30 WITH A HIGH PROPORTION OF LESS-DIFFERENTIATED T CELLS PROMOTES DURABLE RESPONSES IN REFRACTORY CD30+ LYMPHOMA.
Blood
January 2025
Hospital Santa Creu i Sant Pau, Barcelona, Spain.
CD30-directed CART cell therapy (CART30) has limited efficacy in relapsed or refractory patients with CD30+ lymphoma, with a low proportion of durable responses. We have developed an academic CART30 cell product (HSP-CAR30) by combining strategies to improve performance. HSP-CAR30 targets a proximal epitope within the non-soluble part of CD30, and the manufacturing process includes a modulation of ex vivo T cell activation, as well as the addition of interleukin-21 to IL-7 and IL-15 to promote stemness of T cells.
View Article and Find Full Text PDF[Patient with diffuse large B-cell lymphoma: a good example of network in care.].
Recenti Prog Med
January 2025
UO Ematologia, Ospedale San Bortolo, Vicenza.
Chimeric Antigen Receptor T cell (CAR-T) therapy has revolutionized prognosis of patients with diffuse large B-cell lymphoma (DLBCL). Success of CAR-T treatment heavily relies on early referral to the CAR-T center, on a short time of infusion of CAR-T cells from the lymphocyte collection and on a reduced burden of disease. Here we describe the case of a patient with diagnosis of High-grade B-cell lymphoma with MYC and BCL6 rearrangements, transformed from marginal zone lymphoma, referred with a refractory and rapidly progressive disease.
View Article and Find Full Text PDFIntroduction: Pseudoprogression is a complication observed following CAR-T therapy that can mimic disease progression; however, its incidence is not well defined. This phenomenon is driven by a robust inflammatory response due to the recognition of CAR-T cells targeting the lymphoma. Misinterpreting pseudoprogression as true disease progression could result in unnecessary alterations to the treatment regimen.
View Article and Find Full Text PDFDigit Amputation Secondary to COVID-19-Induced Raynaud's Phenomenon.
Cureus
December 2024
Internal Medicine, Centro Hospitalar de Trás-os-Montes e Alto Douro, Vila Real, PRT.
Raynaud's phenomenon (RP) is characterized by episodic vasospasm of the small blood vessels, primarily affecting the fingers and toes. Management includes lifestyle modifications, pharmacological treatments, and in severe cases, surgical interventions. Here we report a case of an 80-year-old male patient with a history of hypertension, dyslipidemia, obesity, and atrial fibrillation who presented to the emergency department with edema, cyanosis, and intense pain in the fingers of both hands following a mild COVID-19 infection (no dyspnea or hypoxemia).
View Article and Find Full Text PDFTherapeutic Effect of Glucose-Insulin-Potassium (GIK) Infusion Therapy in the Treatment of Acute Aluminum Phosphide Poisoning: An Institutional Study.
Cureus
December 2024
Anesthesia Department, PGY2 Anesthesia, Lady Reading Hospital, Peshawar, PAK.
Background: Acute aluminum phosphide (ALP) poisoning presents a significant global medical challenge, particularly in regions where it is commonly used as a pesticide. Despite medical advancements, mortality rates from ALP poisoning remain high. Glucose-insulin-potassium (GIK) infusion therapy has emerged as a potential treatment for ALP poisoning due to its ability to counteract its toxic effects on metabolism and heart function.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!